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Our results seem to suggest that 4-MPR is the major determi­
nant of plasma IGF-1 decline (negative A). This is in keeping 
with our previous observations of a dominant role of 4-MPR in 
determining another principal effect of fenretinide adminis­
tration, namely 3 the decline of plasma retinol levels [5]. We may 
also speculate that the reversal of effect induced by 4-HPR and 
4-MPR concentrations on A IGF-1 as a function of age, is due to 
age-related differences in the metabolism and in tissue distri­
bution of the two compounds, which are partially different both 
in mice [6] and in human mammary gland [7]. 4-MPR appears 
to be less extensively metabolised than 4-HPR and selectively 
concentrated in adipose tissue from which it may be slowly 
released [7], In humans, 4-MPR has a longer half-life than 4- 
HPR [4] , potentially exerting a prolonged effect in circulation, 
while having the same potency as 4-HPR in in vitro differen­
tiation assays [8]. In addition, the metabolism to 4-MPR has 
recently been shown to be critical to the antiproliferative effect 
of 4-HPR on the growth of breast cancer cell lines [9]. Thus, the 
preferential effect of 4-MPR on IGF-1 may have a pharmacologi­
cal explanation or, alternatively, be the result of a selective 
biological action elicited by 4-MPR itself, supporting a leading 
role for 4-MPR in determining some of the main biological 
effects induced in vivo by treatment with fenretinide.
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F otemustine and T amoxifen 
Combination Therapy in Metastatic 
Malignant Melanoma. A Phase II 
Study
C.J.A. Punt, J.H. Tytgat, P. A. van Liessum
and B. Gerard
Sev era l  s t u d ie s  have shown that the addition of tamoxifen to 
chemotherapy may enhance the response rate in patients 
with metastatic malignant melanoma [1-4]. Fotemustine, a 
nitrosurea, has activity against melanoma as a single agent [5-7], 
with a response rate of 24.2% in the largest study with 153 
patients [5]. Tamoxifen enhances in vitro the cytotoxic effect 
of fotemustine on melanoma cell lines expressing oestrogen 
receptors [8]* In patients with metastatic melanoma, high- 
dose tamoxifen may result in a higher complete response rate 
compared with low-dose tamoxifen [9]. We, therefore, initiated 
a phase II study of high-dose tamoxifen and fotemustine in 
patients with metastatic melanoma.
Eligibility criteria included histologically confirmed meta­
static melanoma, measurable progressive disease, age 18-75 
years, WHO performance status < 2 ,  life expectancy ^  3
Table I. Patients' characteristics
No. of patients
Male/female 8/5 
Median age (range) 50 years (33-72)
Median WHO performance (range) 1 (0-1) 
Previous therapy
Radiotherapy 3
Chemotherapy 4
Immunotherapy 2 
Number of metastatic sites
1 5
2 1 
:> 3 7
Metastatic sites
Cerebral 3
Visceral 10
Non'Visceral 10
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Figure 1. Computed tomography scan of the thorax of a patient with 
a large pleural mass due to metastatic melanoma (a) before and 
(b) after treatm ent with high-dose tamoxifen and fotemustine.
months, WBC > 4 X 109/1, platelets 100 x  9/l and no prior
i
treatment with nitrosureas. Treatment consisted of one induc­
tion cycle of tamoxifen 160 mg orally daily from days 1 to 14 and 
fotemustine 100 mg/m2 intravenously (i.v.) on days 8 and 15. 
Patients were evaluated weekly for toxicity and after 6 weeks for 
response. In the absence of tumour progression, as defined by 
WHO criteria3 patients received maintenance cycles of tamox­
ifen 160 mg daily for 7 days and fotemustine 100 mg/m2 on day
8, to be repeated every 3-4 weeks depending on haematological 
recovery. Patients were then evaluated every three cycles for 
response. 14 patients were entered into the study, 1 was ineligible 
and not included in the evaluation. Patient characteristics are 
shown in Table 1. All 13 patients received the induction cycle, 
and 6 patients received a total of 23 maintenance cycles. 
Toxicity was mainly haematological (anaemia/leucopenia/
thrombocytopenia)3 and generally grades 2-3. However, 2 pati­
ents had grade 4 thrombocytopenia. Thromboembolic compli­
cations, as have been described during tamoxifen therapy, did 
not occur [2], 3 patients had grade 2-3 nausea/vomiting.
2 female patients achieved a complete response. One pre­
viously untreated patient had an extensive pleural mass which 
gradually became smaller and completely disappeared after the 
sixth maintenance cycle (Figure 1). After 13 months, a painful 
bone metastasis was visible at a site not previously documented* 
for which she received radiotherapy. She is presently alive at 
24 months without evidence of disease. The other complete 
response occurred in a patient previously treated with chemo­
therapy and radiotherapy who had two subcutaneous lesions of 
13 x 2 and 10 x 2 cm, respectively, which disappeared after 
the induction cycle. She received a total of six maintenance 
cycles. This response is ongoing at 19 months. 3 patients with 
brain metastasis at the start of treatment all progressed at this 
site. The overall response rate was 15% (95% confidence interval 
2--45%). Median overall survival was 6 months (range 1—24+). 
In contrast to others [6], we did not find activity in patients with 
brain metastases, but the number of these patients was too small 
for a definite conclusion. Of note, both responders in our study 
were females, which is in agreement with an earlier observation 
that mainly women appear to benefit from a tamoxifen-contain­
ing regimen [5],
We conclude that this schedule of tamoxifen and fotemustine 
has manageable toxicity, and may result in long-term complete 
responses in patients with metastatic melanoma, even when 
bulky disease is present. The question of whether tamoxifen 
increases the efficacy of treatment with fotemustine has to be 
answered in a prospective randomised study.
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Hepatic Angiosarcoma in a Patient 
With Essential Thrombocythaemia 
and Budd-Chiari Syndrome
C. Marichy, C. Dumontet, Y. Bastion,
C. Rieux, J.Y. Blay, G. Salles, P. Biron
and B. Coiffier
H e pa t ic  angiosarcoma  is a rare tumour, accounting for less 
than 2% of all hepatic tumours [1]. Various environmental 
agents have been reported to be associated with this neoplasm, 
including thorotrast, arsenic and vinyl chloride [2]. We describe 
the case of a patient who developed essential thrombocythaemia 
during childhood, Budd-Chiari syndrome 6 years later and 
hepatic angiosarcoma after another period of 6 years. This is the 
first observation of angiosarcoma occurring in a patient with 
chronic visceral venous stasis.
A 24-year-old female was admitted in September 1991 for 
severe abdominal pain and fever. At the age of 12, she had 
presented with splenomegaly and thrombocytosis, and bone 
marrow examinations confirmed the diagnosis of essential 
thrombocythaemia. Platelet count reached 1.000 giga/1, but the 
parents refused anti-mitotic therapy and the child received 
aspirin only. In April 1986, she presented with Budd-Chiari 
syndrome and underwent shunting with a mesenterico-caval 
anastomosis which allowed partial regression of the liver enlarge­
ment. Anti-mitotic therapy was initiated with hydroxyurea, and 
the patient remained asymptomatic. In September 1991, she 
presented with severe abdominal pain and fever, and physical 
examination revealed marked increase of the liver and bilateral 
pleural effusion. Computerised tomography of the abdomen 
showed multiple hypodense areas in the liver with spontaneously 
hyperdense zones. Magnetic resonance imaging of the liver 
(Figure 1) showed hypointense T1-weighted images and hyper­
intense T2-weighted images, with gadolinium enhancement. A 
histological analysis of one of the hypodense lesions was perfor­
med by needle biopsy and showed an infiltration by sheets of 
poorly differentiated neoplastic cells with broadly anastomosing 
vascular channels, allowing the diagnosis of angiosarcoma. 
Tumoral cells were strongly stained with anti-smooth muscle 
alpha-actin antibody, but reactivity for factor VUI-related anti­
gen could not be performed. Cytological analysis of the pleural 
effusion also demonstrated the presence of malignant cells. The 
patient received 6 courses of a MAID-type regimen (mesna, 
doxorubicin, ifosfamide, dacarbazine) [3], which allowed rapid 
resolution of the pain and fever and a partial reduction of 
the liver enlargement. The patient then received intensive 
chemotherapy with etoposide, ifosfamide and cisplatinum in
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Figure 1. Abdominal magnetic resonance imaging transversal scan 
perform ed at diagnosis. T he  liver is globally enlarged with vast
hypodense areas.
April 1992 with autologous bone marrow transplantation. Unfor­
tunately, the disease progressed in June 1992 and the patient 
died 4 months later.
Superficial angiosarcomas have been reported in patients 
with congenital (Milroy’s disease) or acquired (Stewart-Treves) 
chronic lymph oedema [4, 5]. Irradiation-associated angiosar­
comas have also been reported and they occur predominantly in 
superficial soft tissues [6, 7]. Two cases of liver angiosarcomas 
have been reported in patients treated for Hodgkin’s disease by 
radiochemotherapy, including hepatic irradiation [8]. However, 
this is the first report of angiosarcoma occurring in a patient with 
a myeloproliferative disease and/or with Budd-Chiari syndrome. 
The patient had received for more than 5 years anti-mitotic 
treatment with hydroxyurea, a drug which has not been reported 
to be leukaemogenic or carcinogenic. No cases of angiosarcoma 
have been reported after chemotherapy alone to our knowledge. 
Finally the patient had, 5 years before, developed Budd-Chiari 
syndrome. This condition was responsible for chronic venous 
statis in the liver which may have contributed to the occurrence of 
sarcoma, as has been described in patients with postmastectomy 
lymph oedema developing angiosarcoma. We believe that 
chronic venous statis was the most important factor determining 
the occurrence of angiosarcoma in our patient.
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